Advertisement

The Effect of Prostaglandin E1 on Free Fatty Acid Mobilization and Transport

  • F. Berti
  • R. Lentati
  • M. M. Usardi
  • R. Paoletti

Abstract

Prostaglandin E1 (PGE1: 11 alpha, 15 dihydroxy-9-keto-prost-13 cubic acid) is the best known of a series of lipid soluble acidic compounds (prostaglandins) present in mammalian tissues and biological fluids [1, 2]. The prostaglandins include several closely related components isolated and elucidated from the point of view of their chemical structure by Bergströin et al. [3, 4]. They are.biosynthesized in mammalian organisms from the corresponding polyunsaturated fatty acids (arachidonic, homo-gammalinolinic acid [5] and exhibit biological activity in vitro and in vivo at extremely low concentrations: vasodepression [6], smooth muscle contraction [7, 8] and inhibition of free fatty acid release from adipose tissue [9, 10, 11].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Von Eu1er, U. S., 1934: Arch. Exper. Path. Pharm. 175, 78.CrossRefGoogle Scholar
  2. [2]
    Von Eu1er, U. S., 1939: Skand. Arch. Physiol. 81, 65.CrossRefGoogle Scholar
  3. [3]
    Bergström, S., R. Ryhage, B. Samuelsson, and J. Sjövall, 1962: Acta Chem. Scand. 16, 501.CrossRefGoogle Scholar
  4. [4]
    Bergström, S., F. Dressler, R. Ryhage, B. Samuelsson, and J. Sjövall, 1962: Arkiv. Kenai 19, 563.Google Scholar
  5. [5]
    Samuelsson, B., 1965: Angewandte Chemie 77, 445.CrossRefGoogle Scholar
  6. [6]
    Horton, E. W., 1965: Experientia 21, 113.CrossRefGoogle Scholar
  7. [7]
    Eliansson, R., 1963: Biochem. Pharm. 12, 405.CrossRefGoogle Scholar
  8. [8]
    Horton, E. W., and H. M. Main, 1963: Brit. J. Pharm. 21, 192.Google Scholar
  9. [9]
    Steinberg, D., M. Vaughan, P. J. Nestel, O. Strand, and S. Bergst r ö m, 1964: J. Clin. Invest. 43, 1533.CrossRefGoogle Scholar
  10. [10]
    Bergström, S., 1965: J. Amer. Oil Chem. Soc. 42, 608.CrossRefGoogle Scholar
  11. [11]
    Berti, F., and M. M. Usardi, 1964: Giorn. It. Ateroscl. 2, 261.Google Scholar
  12. [12]
    Unpublished data.Google Scholar
  13. [13]
    Samuelsson, B., 1964: J. Biol. Chem. 239, 4091.Google Scholar
  14. [14]
    Bergström, S., L. A. Carlson, and L. Oro, 1963: Biochem. J. 89, 278.Google Scholar
  15. [15]
    Bergström, S., L. A. Carlson, and L. Oro, 1964: Acta Physiol. Scand. 60, 170.CrossRefGoogle Scholar
  16. [16]
    Steinberg, D., M. Vaughan, P. J. Nestej, and S. Bergström, 1963: Biochem. Pharm. 12, 764.CrossRefGoogle Scholar
  17. [17]
    Berti, F., R. Lentati, and M. M. Usardi, 1965: Ball. Soc. It. Biol. Sper. (in press).Google Scholar
  18. [18]
    Berti, F., R. Lentati, and M. M. Usardi, 1965: Giorn. It. Ateroscl, (in press).Google Scholar
  19. [19]
    Bergström, S., L.A. Carlson, L. G.Ekelund, and L. Oro, 1965: Proc. Soc. Exper. Biol. Med. 118, 110.CrossRefGoogle Scholar
  20. [20]
    Stern, D. C., and R. P. Maickel, 1963: Life Sciences 2, 872.CrossRefGoogle Scholar
  21. [21]
    Carlson, L. A., 1965: Proceedings of the 2nd International Symposium on Drugs Affecting Lipid Metabolism, Milan, September.Google Scholar
  22. [22]
    Carlson, L. A., 1963: Acta Med. Scand. 173, 719.CrossRefGoogle Scholar
  23. [23]
    Vertua, R., M.M. Usardi, R. Bombelli, T. Farkas, and R. Paoletti, 1964: Life Sciences 3, 281.CrossRefGoogle Scholar
  24. [24]
    Farkas, T., R. Vertua, M. M. Usardi, and R. Paoletti, 1964: Life Sciences 3, 821.CrossRefGoogle Scholar
  25. [25]
    Nikkilä, E. A., and A. Hyvärinen, 1962: Clin. Chim. Acta 7, 140.CrossRefGoogle Scholar
  26. [26]
    Doie, V. P., 1956: J. Clin. Invest. 35, 150.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1967

Authors and Affiliations

  • F. Berti
    • 1
  • R. Lentati
    • 1
  • M. M. Usardi
    • 1
  • R. Paoletti
    • 1
  1. 1.Institute of PharmacologyUniversity of MilanMilanItaly

Personalised recommendations